phenol has been researched along with Disease Exacerbation in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Urinary tract infections are among the most common infectious diseases worldwide, primarily caused by uropathogenic Escherichia coli (UPEC) strains that harbor type I pili and P pili on the surface." | 1.51 | Proposed dual antagonist approach for the prevention and treatment of urinary tract infections caused by uropathogenic Escherichia coli. ( Kozina, G; Meštrović, T; Neuberg, M; Ribić, R, 2019) |
| "Phenolization is an effective and safe local adjuvant therapy for GCT." | 1.30 | Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone. ( Baur, A; Dürr, HR; Jansson, V; Maier, M; Refior, HJ, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ribić, R | 1 |
| Meštrović, T | 1 |
| Neuberg, M | 1 |
| Kozina, G | 1 |
| Ying, Z | 1 |
| Chen, M | 1 |
| Xie, X | 1 |
| Wang, X | 1 |
| Kherada, N | 1 |
| Desikan, R | 1 |
| Mihai, G | 1 |
| Burns, P | 1 |
| Sun, Q | 1 |
| Rajagopalan, S | 1 |
| Dürr, HR | 1 |
| Maier, M | 1 |
| Jansson, V | 1 |
| Baur, A | 1 |
| Refior, HJ | 1 |
3 other studies available for phenol and Disease Exacerbation
| Article | Year |
|---|---|
Proposed dual antagonist approach for the prevention and treatment of urinary tract infections caused by uropathogenic Escherichia coli.
Topics: Anti-Bacterial Agents; Disease Progression; Epithelial Cells; Escherichia coli Infections; Fimbriae, | 2019 |
Lipoicmethylenedioxyphenol Reduces Experimental Atherosclerosis through Activation of Nrf2 Signaling.
Topics: Animals; Atherosclerosis; Blood Vessels; Chemotaxis, Leukocyte; Disease Models, Animal; Disease Prog | 2016 |
Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Child; Disease Progression; Giant Ce | 1999 |